Press coverage about Apellis Pharmaceuticals (NASDAQ:APLS) has been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Apellis Pharmaceuticals earned a coverage optimism score of 0.07 on Accern’s scale. Accern also assigned news stories about the company an impact score of 47.8053081000412 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

A number of equities research analysts recently issued reports on the stock. Evercore ISI assumed coverage on shares of Apellis Pharmaceuticals in a report on Monday, December 4th. They issued an “outperform” rating for the company. Citigroup assumed coverage on shares of Apellis Pharmaceuticals in a report on Monday, December 4th. They issued a “buy” rating and a $23.00 price objective for the company. Finally, JPMorgan Chase & Co. assumed coverage on shares of Apellis Pharmaceuticals in a report on Monday, December 4th. They issued an “overweight” rating and a $31.00 price objective for the company.

Shares of Apellis Pharmaceuticals (NASDAQ:APLS) opened at $20.26 on Thursday. The stock has a market cap of $1,020.00 and a price-to-earnings ratio of -25.33. Apellis Pharmaceuticals has a fifty-two week low of $12.45 and a fifty-two week high of $25.49.

In other Apellis Pharmaceuticals news, major shareholder Global Strategic Fund I. Venbio acquired 127,515 shares of the firm’s stock in a transaction that occurred on Monday, November 13th. The stock was purchased at an average cost of $14.00 per share, for a total transaction of $1,785,210.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

TRADEMARK VIOLATION NOTICE: “Somewhat Positive News Coverage Somewhat Unlikely to Impact Apellis Pharmaceuticals (APLS) Share Price” was posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be read at https://theolympiareport.com/2018/01/11/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-apellis-pharmaceuticals-apls-share-price.html.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The Company’s lead compounds are designed to inhibit complement component 3 (C3), the central protein in the complement cascade.

Insider Buying and Selling by Quarter for Apellis Pharmaceuticals (NASDAQ:APLS)

Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.